Genome-wide association study of phenotypes measuring progression from first cocaine or opioid use to dependence reveals novel risk genes.

Sherva R, Zhu C, Wetherill L, Edenberg HJ, Johnson E, Degenhardt L, Agrawal A, Martin NG, Nelson E, Kranzler HR, Gelernter J, Farrer LA. Genome-wide association study of phenotypes measuring progression from first cocaine or opioid use to dependence reveals novel risk genes. Exploration of medicine. 2021 Feb 28; 2:60-73.

Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects.

If you have VA-Intranet access, click here for more information vaww.hsrd.research.va.gov/dimensions/

VA staff not currently on the VA network can access Dimensions by registering for an account using their VA email address.    Search Dimensions for VA for this citation
* Don't have VA-internal network access or a VA email address? Try searching the free-to-the-public version of Dimensions

Search for Abstract from PubMed

---

Abstract:

Aim: Substance use disorders (SUD) result in substantial morbidity and mortality worldwide. Opioids, and to a lesser extent cocaine, contribute to a large percentage of this health burden. Despite their high heritability, few genetic risk loci have been identified for either opioid or cocaine dependence (OD or CD, respectively). A genome-wide association study of OD and CD related phenotypes reflecting the time between first self-reported use of these substances and a first DSM-IV dependence diagnosis was conducted. Methods: Cox proportional hazards regression in a discovery sample of 6,188 African-Americans (AAs) and 6,835 European-Americans (EAs) participants in a genetic study of multiple substance dependence phenotypes were used to test for association between genetic variants and these outcomes. The top findings were tested for replication in two independent cohorts. Results: In the discovery sample, three independent regions containing variants associated with time to dependence at < 5 x 10 were identified, one (rs61835088 = 1.03 x 10) for cocaine in the combined EA-AA meta-analysis in the gene on chromosome 1, and two for opioids in the AA portion of the sample in intergenic regions of chromosomes 4 (rs4860439, = 1.37 x 10) and 9 (rs7032521, = 3.30 x 10). After meta-analysis with data from the replication cohorts, the signal at rs61835088 improved (HR = 0.87, = 3.71 x 10 and an intergenic SNP on chromosome 21 (rs2825295, HR = 1.14, = 2.57 x 10) that missed the significance threshold in the AA discovery sample became genome-wide significant (GWS) for CD. Conclusions: Although the two GWS variants are not in genes with obvious links to SUD biology and have modest effect sizes, they are statistically robust and show evidence for association in independent samples. These results may point to novel pathways contributing to disease progression and highlight the utility of related phenotypes to better understand the genetics of SUDs.